Risk Factors and Clinical Outcomes of Candidemia Associated With Severe COVID-19
IMPORTANCE:. COVID-19 can cause serious illness requiring multimodal treatment and is associated with secondary infections. Studies have suggested an increased risk of fungal infections, including candidemia following severe COVID-19 though understanding of risk factors and clinical outcomes remains...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer
2022-09-01
|
| Series: | Critical Care Explorations |
| Online Access: | http://journals.lww.com/10.1097/CCE.0000000000000762 |
| _version_ | 1811204285624483840 |
|---|---|
| author | Deepali Dixit, PharmD, BCPS, BCCCP, FCCM Polly Jen, PharmD, BCPS, BCIDP, AAHIVP Tyler D. Maxwell, BS, PharmD Steven Smoke, PharmD, BCPS, BCIDP James Andrew McCracken, PharmD Maria Cardinale-King, PharmD, BCCCP Aditi Haribhakti, PharmD Candidate Purvi Patel, MD Eris Cani, BS, PharmD, BCIDP, BCPS Seohyun (Claudia) Choi, PharmD, BCCCP Sugeet Jagpal, MD Tilly Varughese, MD Luis L. Tatem, MD Tanaya Bhowmick, MD |
| author_facet | Deepali Dixit, PharmD, BCPS, BCCCP, FCCM Polly Jen, PharmD, BCPS, BCIDP, AAHIVP Tyler D. Maxwell, BS, PharmD Steven Smoke, PharmD, BCPS, BCIDP James Andrew McCracken, PharmD Maria Cardinale-King, PharmD, BCCCP Aditi Haribhakti, PharmD Candidate Purvi Patel, MD Eris Cani, BS, PharmD, BCIDP, BCPS Seohyun (Claudia) Choi, PharmD, BCCCP Sugeet Jagpal, MD Tilly Varughese, MD Luis L. Tatem, MD Tanaya Bhowmick, MD |
| author_sort | Deepali Dixit, PharmD, BCPS, BCCCP, FCCM |
| collection | DOAJ |
| description | IMPORTANCE:. COVID-19 can cause serious illness requiring multimodal treatment and is associated with secondary infections. Studies have suggested an increased risk of fungal infections, including candidemia following severe COVID-19 though understanding of risk factors and clinical outcomes remains unclear.
OBJECTIVES:. To describe clinical characteristics, outcomes and risk factors of candidemia among patients hospitalized with severe COVID-19.
DESIGN, SETTING, AND PARTICIPANTS:. A multicenter, case-control study of patients with severe COVID-19 was conducted to evaluate risk factors and clinical outcomes in patients who developed candidemia between August 2020 and August 2021.
MAIN OUTCOMES AND MEASURES:. Chart review evaluating institutional and patient demographics, clinical and mycological characteristics, concomitant interventions (antibiotics, immunosuppressive agents, parenteral nutrition, degree of oxygen support, mechanical ventilation, surgery), treatment regimens, and outcomes (length of stay and discharge disposition)
RESULTS:. A total of 275 patients were enrolled in the study, including 91 patients with severe COVID-19 and subsequent candidemia and 184 with severe COVID-19 without candidemia. Most patients received antibiotics prior to candidemia episode (93%), while approximately one-quarter of patients received biologic for COVID-19. In-hospital mortality was significantly higher in the cases compared with the controls (68% vs 40%; p < 0.01). Candida albicans was the most common (53%), followed by C. glabrata (19%). Use of central lines, biologic, and paralytics were independent risk factors for candidemia.
CONCLUSIONS AND RELEVANCE:. Candidemia following COVID-19 infection is a concern that requires clinical consideration and patient monitoring. Risk factors for the development of candidemia in the setting of COVID-19 infection are largely consistent with traditional risk factors for candidemia in hospitalized patients. |
| first_indexed | 2024-04-12T03:10:23Z |
| format | Article |
| id | doaj.art-f65c9dabcfe04d79bc7011b82a081de8 |
| institution | Directory Open Access Journal |
| issn | 2639-8028 |
| language | English |
| last_indexed | 2024-04-12T03:10:23Z |
| publishDate | 2022-09-01 |
| publisher | Wolters Kluwer |
| record_format | Article |
| series | Critical Care Explorations |
| spelling | doaj.art-f65c9dabcfe04d79bc7011b82a081de82022-12-22T03:50:23ZengWolters KluwerCritical Care Explorations2639-80282022-09-0149e076210.1097/CCE.0000000000000762202209000-00012Risk Factors and Clinical Outcomes of Candidemia Associated With Severe COVID-19Deepali Dixit, PharmD, BCPS, BCCCP, FCCM0Polly Jen, PharmD, BCPS, BCIDP, AAHIVP1Tyler D. Maxwell, BS, PharmD2Steven Smoke, PharmD, BCPS, BCIDP3James Andrew McCracken, PharmD4Maria Cardinale-King, PharmD, BCCCP5Aditi Haribhakti, PharmD Candidate6Purvi Patel, MD7Eris Cani, BS, PharmD, BCIDP, BCPS8Seohyun (Claudia) Choi, PharmD, BCCCP9Sugeet Jagpal, MD10Tilly Varughese, MD11Luis L. Tatem, MD12Tanaya Bhowmick, MD131 Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ.2 Newark Beth Israel Medical Center, Newark, NJ.3 Touro College of Pharmacy, New York, NY.4 Cooperman Barnabas Medical Center, Livingston, NJ.1 Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ.1 Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ.1 Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ.5 Division of Infectious Disease, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ.3 Touro College of Pharmacy, New York, NY.6 University of Washington, School of Pharmacy, Seattle, WA.7 Division of Pulmonary and Critical Care Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ.5 Division of Infectious Disease, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ.8 SUNY Downstate Medical Center, Brooklyn, NY.5 Division of Infectious Disease, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ.IMPORTANCE:. COVID-19 can cause serious illness requiring multimodal treatment and is associated with secondary infections. Studies have suggested an increased risk of fungal infections, including candidemia following severe COVID-19 though understanding of risk factors and clinical outcomes remains unclear. OBJECTIVES:. To describe clinical characteristics, outcomes and risk factors of candidemia among patients hospitalized with severe COVID-19. DESIGN, SETTING, AND PARTICIPANTS:. A multicenter, case-control study of patients with severe COVID-19 was conducted to evaluate risk factors and clinical outcomes in patients who developed candidemia between August 2020 and August 2021. MAIN OUTCOMES AND MEASURES:. Chart review evaluating institutional and patient demographics, clinical and mycological characteristics, concomitant interventions (antibiotics, immunosuppressive agents, parenteral nutrition, degree of oxygen support, mechanical ventilation, surgery), treatment regimens, and outcomes (length of stay and discharge disposition) RESULTS:. A total of 275 patients were enrolled in the study, including 91 patients with severe COVID-19 and subsequent candidemia and 184 with severe COVID-19 without candidemia. Most patients received antibiotics prior to candidemia episode (93%), while approximately one-quarter of patients received biologic for COVID-19. In-hospital mortality was significantly higher in the cases compared with the controls (68% vs 40%; p < 0.01). Candida albicans was the most common (53%), followed by C. glabrata (19%). Use of central lines, biologic, and paralytics were independent risk factors for candidemia. CONCLUSIONS AND RELEVANCE:. Candidemia following COVID-19 infection is a concern that requires clinical consideration and patient monitoring. Risk factors for the development of candidemia in the setting of COVID-19 infection are largely consistent with traditional risk factors for candidemia in hospitalized patients.http://journals.lww.com/10.1097/CCE.0000000000000762 |
| spellingShingle | Deepali Dixit, PharmD, BCPS, BCCCP, FCCM Polly Jen, PharmD, BCPS, BCIDP, AAHIVP Tyler D. Maxwell, BS, PharmD Steven Smoke, PharmD, BCPS, BCIDP James Andrew McCracken, PharmD Maria Cardinale-King, PharmD, BCCCP Aditi Haribhakti, PharmD Candidate Purvi Patel, MD Eris Cani, BS, PharmD, BCIDP, BCPS Seohyun (Claudia) Choi, PharmD, BCCCP Sugeet Jagpal, MD Tilly Varughese, MD Luis L. Tatem, MD Tanaya Bhowmick, MD Risk Factors and Clinical Outcomes of Candidemia Associated With Severe COVID-19 Critical Care Explorations |
| title | Risk Factors and Clinical Outcomes of Candidemia Associated With Severe COVID-19 |
| title_full | Risk Factors and Clinical Outcomes of Candidemia Associated With Severe COVID-19 |
| title_fullStr | Risk Factors and Clinical Outcomes of Candidemia Associated With Severe COVID-19 |
| title_full_unstemmed | Risk Factors and Clinical Outcomes of Candidemia Associated With Severe COVID-19 |
| title_short | Risk Factors and Clinical Outcomes of Candidemia Associated With Severe COVID-19 |
| title_sort | risk factors and clinical outcomes of candidemia associated with severe covid 19 |
| url | http://journals.lww.com/10.1097/CCE.0000000000000762 |
| work_keys_str_mv | AT deepalidixitpharmdbcpsbcccpfccm riskfactorsandclinicaloutcomesofcandidemiaassociatedwithseverecovid19 AT pollyjenpharmdbcpsbcidpaahivp riskfactorsandclinicaloutcomesofcandidemiaassociatedwithseverecovid19 AT tylerdmaxwellbspharmd riskfactorsandclinicaloutcomesofcandidemiaassociatedwithseverecovid19 AT stevensmokepharmdbcpsbcidp riskfactorsandclinicaloutcomesofcandidemiaassociatedwithseverecovid19 AT jamesandrewmccrackenpharmd riskfactorsandclinicaloutcomesofcandidemiaassociatedwithseverecovid19 AT mariacardinalekingpharmdbcccp riskfactorsandclinicaloutcomesofcandidemiaassociatedwithseverecovid19 AT aditiharibhaktipharmdcandidate riskfactorsandclinicaloutcomesofcandidemiaassociatedwithseverecovid19 AT purvipatelmd riskfactorsandclinicaloutcomesofcandidemiaassociatedwithseverecovid19 AT eriscanibspharmdbcidpbcps riskfactorsandclinicaloutcomesofcandidemiaassociatedwithseverecovid19 AT seohyunclaudiachoipharmdbcccp riskfactorsandclinicaloutcomesofcandidemiaassociatedwithseverecovid19 AT sugeetjagpalmd riskfactorsandclinicaloutcomesofcandidemiaassociatedwithseverecovid19 AT tillyvarughesemd riskfactorsandclinicaloutcomesofcandidemiaassociatedwithseverecovid19 AT luisltatemmd riskfactorsandclinicaloutcomesofcandidemiaassociatedwithseverecovid19 AT tanayabhowmickmd riskfactorsandclinicaloutcomesofcandidemiaassociatedwithseverecovid19 |